Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

Background: German authorities reimburse migraine prevention with erenumab only in patients who previously did not have therapeutic success with at least five oral prophylactics or have contraindications to such. In this real-world analysis, we assessed treatment response to erenumab in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffaelli, Bianca, Kalantzis, Rea, Mecklenburg, Jasper, Overeem, Lucas Hendrik, Neeb, Lars, Gendolla, Astrid, Reuter, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270347/
https://www.ncbi.nlm.nih.gov/pubmed/32547474
http://dx.doi.org/10.3389/fneur.2020.00417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270347/
https://www.ncbi.nlm.nih.gov/pubmed/32547474
http://dx.doi.org/10.3389/fneur.2020.00417

Ejemplares similares